Comparative Pharmacology
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus KONVOMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus KONVOMEP.
ESLICARBAZEPINE ACETATE vs KONVOMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
None Documented
None Documented
Clinical Note
moderateEslicarbazepine acetate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateEslicarbazepine acetate + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateCyclophosphamide + Eslicarbazepine acetate
"The metabolism of Eslicarbazepine acetate can be decreased when combined with Cyclophosphamide."
Clinical Note
moderateTerminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min).
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant
Phenytoin + Eslicarbazepine acetate
"The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin."